Credit Suisse Ag Spruce Biosciences, Inc. Transaction History

Credit Suisse Ag

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$1.28 - $2.23 $6 - $11	5 New	5 $0
Q2 2021 Aug 16, 2021	SELL	$10.12 - $17.46 $241,857 - $417,276	-23,899 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$14.8 - $25.79 $26,847 - $46,783	-1,814 Reduced 7.05%	23,899 $397,000
Q4 2020 Feb 12, 2021	BUY	$15.38 - $32.42 $395,465 - $833,615	25,713 New	25,713 $625,000

15.4M

16.7K

1.1K

Ticker SPRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,560,200
Market Cap $11.5M
Description
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which i...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.